Skip to Content
Søk Menu

Real-world data on effectiveness of durvalumab after chemoradiotherapy

Real-world data on effectiveness of durvalumab after PACIFIC-R real-world trial confirms effectiveness of durvalumab in patients with unresectable stage III non–small cell lung cancer (NSCLC), concludes Professor Nicolas Girard in this BestPractice Nordic MEDtalk.
Nocolas_gardi

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video 9:01

Karonudib, et potensielt legemiddel til bruk ved lymfom

/ Thea Kristin Våtsveen
KjemoterapiLymfom
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynekologisk kreft Play the Video 9:01
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynekologisk kreft Play the Video 5:06
Ma Pilar Barretina-Ginesta

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

/ Ma Pilar Barretina-Ginesta
ESMO21Gynekologisk kreft Play the Video 6:03
Roy S. Herbst

Clinical perspective of the COAST-study for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21LungekreftNSCLC Play the Video 2:50
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21NSCLC Play the Video 4:03
Camillo Porta

New quality of life data with immune-based treatment of metastatic renal cell carcinoma

/ Camillo Porta
ESMO21Hudkreft Play the Video 9:16
Jared Weiss

Promising clinical results for heavily pretreated patients with colorectal cancer

/ Jared Weiss
ESMO21Kolorektal kreft Play the Video 5:32
Back to top